Founded on seminal work from leading scientists, Mozart is developing biologics to target a novel T cell network of pathogenic CD4 and cytolytic-regulatory CD8 T cells.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/27/21 | $55,000,000 | Series A |
Alexandria Venture Investments Altitude Life Science Ventures ARCH Venture Partners  Eli Lilly and Company Leaps by Bayer MRL Ventures Fund Sofinnova Ventures | undisclosed |
